BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fuse Science, Inc. Breaks Code on Patchless Insulin Delivery With Simple Roll-On


10/22/2012 10:34:13 AM

MIAMI LAKES, Fla., Oct. 22, 2012 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) an innovative company that possesses proprietary delivery technology set to redefine how consumers receive energy, medicines, vitamins and minerals, today provides further details on their most recent research results. The study results present what the Company believes to be several scientific firsts in transdermal delivery through the epidermis. The Company possesses proprietary patchless delivery technology, which Fuse now knows with certainty that can deliver a wide range of compounds through the epidermis in a simple roll-on application.

The study tested a wide canvass of compounds, with varying physiochemical characteristics, to document the range of compounds that can be encapsulated in the Company's proprietary delivery technology. Success in each area opens the door to a host of product categories that can be significantly improved through utilization of the Company's proprietary technology. The molecular structure of the test cells in the study ranged from small, water soluble and rigid molecules to large, greasy and flexible molecules with a representative sample from over 80% of common compound structures. The Test Cells were as follows: Caffeine, Nicotinic Acid, Folic Acid, Tocopherol Acetate, Polyethylene Glycol, Estradiol, Paclitaxel, and Insulin.

Every compound tested in this study successfully penetrated the epidermis at distinctive rates with unique penetration profiles. This represents several scientific firsts and establishes infinite new ways to effectively deliver medicines and nutrition in humans and animals in a patchless roll-on application.

The conclusion of the study centered around three main points:

  • Fuse Science possesses proprietary encapsulation technology, which can deliver a variety of compounds with different physiochemical characteristics across the epidermis at distinctive rates and unique penetration profiles in a simple roll-on.
  • The patchless encapsulation formula can deliver significant amounts of larger, rigid, lipophilic molecules to smaller, flexible, hydrophilic molecules across the epidermis.
  • The diabetic Insulin drug and the cancer drug Paclitaxel maintained consistent delivery through the epidermis at each time interval through the 24-hour time-point.

"Today's scientific results indicate that Fuse Science possesses capabilities to deliver over 80% of all molecular structures with our proprietary technology through the epidermis to the blood stream," said Brian Tuffin, Fuse Science, Inc. CEO. "This opens the door for making the $3.0 billion dollar patch business obsolete and completely redefining the injectable and consumable delivery market. Of largest benefit is the present ability of Fuse Science to deliver Insulin in this roll-on form. We see this as the first step in replacing the need for daily injections by diabetic sufferers around the world."

Compliance is an ongoing issue with the young and elderly populations. This research sets the stage to eliminate the struggles of a parent to get the proper medication and nutrition into their child. Envision a simple roll-on to the arm instead of an injection or attempting to get the child to swallow their medication, vitamins or cough syrup. At the same time, consider the elderly trying to swallow the multiple medications required daily becoming a seamless exercise. The results demonstrate that Fuse Science has opened the door to a much easier form of nutrition and medication delivery that can significantly change how we all deal with the consumption of these life essentials.

Fuse Science will continue its work with the New York-based investment banking firm Atlas Strategic Advisors (www.atlasadvisors.com) to explore strategic transactions involving Fuse's proprietary technology. Additionally, Fuse Science will be advised by Gaurav Kapoor, former Managing Partner and Principal at New England Consulting Group, where he worked for 15 years, leading landmark M&A and licensing transactions in the pharmaceutical and consumer package goods industries.

About Fuse Science, Inc.

Fuse Science Inc. (OTCQB: DROP), is an innovative holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly either through a topical gel roll-on or alternatively in a concentrated "DROP" form that is simply applied under the tongue. Fuse Science's technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

For more information:

To schedule an interview:

Fuse Science, Inc.

Gus DeQuesada

Investor Relations

Michelsen Advertising

Direct: (305) 503-3873, Ext. 2

C-305-733-1410 / 786-488-7138

Email: ir@fusescience.com

prnews@michelsenadvertising.com

Safe Harbor Statement

Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings located at www.sec.gov. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Fuse Science, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES